Actively Recruiting
SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy
Led by The First Affiliated Hospital of Xiamen University · Updated on 2025-07-01
20
Participants Needed
2
Research Sites
164 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a single-arm, open-label, prospective, and exploratory investigation aimed at examining the short-term efficacy, specifically the objective response rate (ORR), of SBRT combined with Nimotuzumab followed by Tislelizumab in patients with recurrent/metastatic nasopharyngeal carcinoma who have experienced oligoprogression (1-5 metastatic lesions) after immunotherapy.
CONDITIONS
Official Title
SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathologically confirmed non-keratinizing nasopharyngeal carcinoma
- Recurrent or metastatic nasopharyngeal carcinoma with 1-5 progressing metastatic lesions after first-line anti-PD-1 immunotherapy failure
- Eligible for SBRT, Tislelizumab, and Nimotuzumab treatment
- No history of other malignant tumors
- Male or female aged 18 to 75 years
- Liver function with total bilirubin upper limit of normal (ULN), AST and ALT 2.5 times ULN, alkaline phosphatase 5 times ULN
- Renal function with creatinine clearance 80 mL/min
- Hematological tests with absolute neutrophil count 2 x 10^9/L, platelet count 100 x 10^9/L, and hemoglobin 9 g/dL
- No severe dysfunction of heart, lung, or other vital organs
- Performance Status score 2
You will not qualify if you...
- Declining to sign the informed consent form
- Inability to comply with regular follow-ups due to psychological, social, family, or geographical reasons
- Receiving other experimental treatments during the clinical study
- Severe, uncontrolled infections or medical conditions
- Major organ dysfunction or decompensated heart, lung, kidney, or liver failure preventing radiotherapy or immunotherapy
- Conditions affecting drug handling, such as mental or central nervous system abnormalities, chronic diarrhea, ascites, or pleural effusion
- Recent overexposure to glucocorticoids within 2 weeks before immunotherapy
- Long-term use of immunosuppressive agents following organ transplantation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China, 361003
Enrolling by Invitation
2
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China, 361003
Actively Recruiting
Research Team
S
San-Gang Wu, MD., PHD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here